Topix Appoints Brenda Wu as New President & CEO

Skincare and Beauty Industry Veteran to Lead Topix into the Future

AMITYVILLE, N.Y.–(BUSINESS WIRE)–Topix Pharmaceuticals, the leading independent provider of premium,
custom and branded skincare, today announced the appointment of Brenda
Wu as President and CEO. Brenda adds these responsibilities to her
existing role as President and CEO of Topix-owned DERMA E, one of the
fasting growing clean, green and accessible skincare brands. Wu will
lead Topix, which is backed by New Mountain Capital, a growth-oriented
investment firm that currently manages more than $20 billion in assets,
into its next phase of growth. New Mountain Capital invested in Topix to
provide equity capital to execute a growth strategy, including both
organic and acquisition-led growth.

In her new role, Wu will lead all aspects of revenue and profit growth,
including R&D, new product development, sales & marketing, operations
and strategic corporate development. Under Wu’s leadership, Topix will
continue to build awareness of its world-class skincare products by
investing in sales, marketing and digital capabilities as well as
furthering the Company’s leadership in R&D, physician commitment and
turnkey service.

Wu joins Topix after more than a decade of success at L’Oréal, where she
led trusted brands such as SkinCeuticals, Giorgio Armani Beauty, Lancôme
and Kiehl’s. At L’Oréal, Wu served as U.S. General Manager of
SkinCeuticals and under Wu’s leadership, SkinCeuticals became the #1
professional skincare brand in the U.S. Prior to L’Oréal, Wu led teams
in retail merchandising at Banana Republic, digital marketing at AOL
Time Warner and strategy consulting at Bain & Company. Wu is a graduate
of Harvard College, holds a M.B.A. from Harvard Business School and has
also attended Harvard Law School and the Christine Valmy Esthetics

“Brenda is a proven leader with an exceptional track-record of
delivering results through dedication to her teams, ongoing innovation
and partnership with customers,” added Andre Moura, Managing Director at
New Mountain Capital and Chairman of the Board of Directors of Topix.
“We couldn’t be more excited to see Brenda lead the Topix business into
the future as we continue to support increased investments in Topix to
better serve our customers.”

“I am thrilled and honored to join Topix as President and CEO,”
commented Wu. “Topix was built on a foundation of the most advanced
research and development and clinically proven formulas that are tested
and customized for dermatologists. I look forward to furthering our
mission of developing cutting-edge technologies, building our physician
partners’ unique brands and helping physicians build their own
businesses. I am excited to be working with the Topix team to take the
business to new heights.”

About Topix

Topix is the independent leader in skincare with a differentiated
portfolio of clinically-proven products, custom and consumer brands sold
across high-growth channels. Topix was founded in 1981 and built its
reputation in the physician market where it is the largest provider of
premium, customized and branded skincare products, partnering with over
3,000 physicians in the U.S. Topix’s portfolio of products are
clinically-validated and manufactured in the Company’s state-of-the-art,
FDA-registered facility in New York. For more information on Topix,
please visit:

About New Mountain Capital

New Mountain Capital is a New York based investment firm that emphasizes
business building and non-cyclical growth, rather than debt, as it
pursues long-term capital appreciation. The firm currently manages
private equity, public equity, and credit funds with over $20 billion in
assets under management. New Mountain seeks out what it believes to be
the highest quality growth leaders in carefully selected industry
sectors and then works intensively with management to build the value of
these companies. For more information on New Mountain Capital, please


AMP3 PR, Ashley Lutzker (212)-677-2929